Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Current Assets (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Current Assets for 13 consecutive years, with $942.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets fell 2.44% year-over-year to $942.1 million, compared with a TTM value of $942.1 million through Dec 2025, down 2.44%, and an annual FY2025 reading of $942.1 million, down 2.44% over the prior year.
  • Current Assets was $942.1 million for Q4 2025 at Agios Pharmaceuticals, down from $1.0 billion in the prior quarter.
  • Across five years, Current Assets topped out at $2.4 billion in Q1 2021 and bottomed at $632.1 million in Q2 2024.
  • Average Current Assets over 5 years is $998.5 million, with a median of $942.1 million recorded in 2025.
  • The sharpest move saw Current Assets skyrocketed 301.02% in 2021, then plummeted 58.59% in 2022.
  • Year by year, Current Assets stood at $1.1 billion in 2021, then decreased by 21.75% to $832.8 million in 2022, then rose by 0.13% to $833.8 million in 2023, then increased by 15.8% to $965.6 million in 2024, then dropped by 2.44% to $942.1 million in 2025.
  • Business Quant data shows Current Assets for AGIO at $942.1 million in Q4 2025, $1.0 billion in Q3 2025, and $1.0 billion in Q2 2025.